Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Jun 4

PMID 32489466

Citations 87

Authors

Chikezie O Madu

Stephanie Wang

Chinua O Madu

Yi Lu

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is a significant event in a wide range of healthy and diseased conditions. This process frequently involves vasodilation and an increase in vascular permeability. Numerous players referred to as angiogenic factors, work in tandem to facilitate the outgrowth of endothelial cells (EC) and the consequent vascularity. Conversely, angiogenic factors could also feature in pathological conditions. Angiogenesis is a critical factor in the development of tumors and metastases in numerous cancers. An increased level of angiogenesis is associated with decreased survival in breast cancer patients. Therefore, a good understanding of the angiogenic mechanism holds a promise of providing effective treatments for breast cancer progression, thereby enhancing patients' survival. Disrupting the initiation and progression of this process by targeting angiogenic factors such as vascular endothelial growth factor (Vegf)-one of the most potent member of the VEGF family- or by targeting transcription factors, such as Hypoxia-Inducible Factors (HIFs) that act as angiogenic regulators, have been considered potential treatment options for several types of cancers. The objective of this review is to highlight the mechanism of angiogenesis in diseases, specifically its role in the progression of malignancy in breast cancer, as well as to highlight the undergoing research in the development of angiogenesis-targeting therapies.

Citing Articles

PFDN1 silencing disrupts critical cancer pathways in triple-negative breast cancer: investigating migration, cell cycle, and apoptosis as a new target therapy.

Alokda A, Soffar A, Yousef A, Ibrahim F, El-Sewedy T, Elmetwalli A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40063241 DOI: 10.1007/s00210-025-03975-6.

Epigenetic regulation of angiogenesis and its therapeutics.

Choi D Genomics Inform. 2025; 23(1):4.

PMID: 39934895 PMC: 11817428. DOI: 10.1186/s44342-025-00038-3.

Canine mammary tumors as a promising adjunct preclinical model for human breast cancer research: similarities, opportunities, and challenges.

Bhutta Z, Choi K Arch Pharm Res. 2025; 48(1):43-61.

PMID: 39752109 DOI: 10.1007/s12272-024-01524-y.

Gold nanoparticles mediate suppression of angiogenesis and breast cancer growth via MMP-9/NF-κB/mTOR and PD-L1/PD-1 signaling: integrative in vitro validation and network pharmacology insights.

Elmetwalli A, El-Sewedy T, Hassan M, Abdel-Monem M, Hassan J, Ismail N Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39718609 DOI: 10.1007/s00210-024-03682-8.

Single-cell spatial mapping reveals alteration of cell type composition and tissue microenvironment during early colorectal cancer formation.

Guha T, Esplin E, Horning A, Chiu R, Paul K, Weimer A bioRxiv. 2024; .

PMID: 39605357 PMC: 11601668. DOI: 10.1101/2024.11.20.622725.

References

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

Semenza G . HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl):S62-7. DOI: 10.1016/s1471-4914(02)02317-1. View

Meyer M, Clauss M, Waltenberger J, Augustin H, Ziche M, Lanz C . A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 1999; 18(2):363-74. PMC: 1171131. DOI: 10.1093/emboj/18.2.363. View

Linardou H, Kalogeras K, Kronenwett R, Kouvatseas G, Wirtz R, Zagouri F . The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative.... Breast Cancer Res. 2012; 14(6):R145. PMC: 4053134. DOI: 10.1186/bcr3354. View

Boehm T, Folkman J, Browder T, OReilly M . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390(6658):404-7. DOI: 10.1038/37126. View

Escudier B, Gore M . Axitinib for the management of metastatic renal cell carcinoma. Drugs R D. 2011; 11(2):113-26. PMC: 3585900. DOI: 10.2165/11591240-000000000-00000. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

10.

Volpert O, Tolsma S, Pellerin S, Feige J, Chen H, Mosher D . Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun. 1995; 217(1):326-32. DOI: 10.1006/bbrc.1995.2780. View

11.

Risau W, Flamme I . Vasculogenesis. Annu Rev Cell Dev Biol. 1995; 11:73-91. DOI: 10.1146/annurev.cb.11.110195.000445. View

12.

Jarvelainen H, Sainio A, Wight T . Pivotal role for decorin in angiogenesis. Matrix Biol. 2015; 43:15-26. PMC: 4560244. DOI: 10.1016/j.matbio.2015.01.023. View

13.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

14.

Sgadari C, Angiolillo A, Tosato G . Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996; 87(9):3877-82. View

15.

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

16.

Hutson T, Escudier B, Esteban E, Bjarnason G, Lim H, Pittman K . Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2013; 32(8):760-7. PMC: 5569683. DOI: 10.1200/JCO.2013.50.3961. View

17.

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R . Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006; 5(10):835-44. DOI: 10.1038/nrd2130. View

18.

Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet J, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-40. DOI: 10.1158/1535-7163.MCT-08-0013. View

19.

Arora A, Scholar E . Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005; 315(3):971-9. DOI: 10.1124/jpet.105.084145. View

20.

Norgauer J, Metzner B, Schraufstatter I . Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol. 1996; 156(3):1132-37. View